Logo

Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

Share this

Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe

Shots:

  • Kaken to receive an up front in cash and is eligible to receive milestones and royalties on the sales of the product. Almirall plans to have a pre-submission meeting with regulatory authorities in next year to prepare the approval of the product in the EU
  • Almirall get the exclusive rights for the development and commercialization of the topical antifungal formulation of efinaconazole in the EU
  • Efinaconazole is a triazole antifungal therapy indicated for the treatment of fungal infection of the nail called onychomycosis

  | Ref: PR Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions